APM icon

Aptorum Group

1.67 USD
+0.04
2.45%
Updated Jul 30, 2:53 PM EDT
1 day
2.45%
5 days
-14.80%
1 month
83.52%
3 months
77.85%
6 months
35.77%
Year to date
-24.09%
1 year
-48.77%
5 years
-95.53%
10 years
-98.84%
 

About: Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Employees: 1

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding

Funds holding: 4 [Q4 2024] → 8 (+4) [Q1 2025]

0.14% more ownership

Funds ownership: 1.62% [Q4 2024] → 1.76% (+0.14%) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

41% less capital invested

Capital invested by funds: $134K [Q4 2024] → $79.2K (-$54.5K) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for APM.

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.
Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
Neutral
GlobeNewsWire
3 months ago
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Neutral
Business Wire
6 months ago
Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability
BELLEVUE, Wash.--(BUSINESS WIRE)--Synology launches the ActiveProtect series a unified enterprise backup solution set to disrupt the current data backup market.
Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability
Neutral
GlobeNewsWire
6 months ago
Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at an offering price of $2.00 per share.
Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
Neutral
Business Wire
7 months ago
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. “Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary tra.
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
Neutral
Business Wire
1 year ago
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented, “Throughout 2023, we have maintained a.
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
Positive
InvestorPlace
1 year ago
5 Investors Betting Big on Aptorum (APM) Group
Clinical-stage biopharmaceutical firm Aptorum (NASDAQ: APM ) is seeing its market value rise dramatically today on a merger between its wholly owned subsidiary and an artificial intelligence (AI) and automation platform. A combination of AI enthusiasm and some support from institutional investors is likely what's helping APM stock rocket higher.
Positive
InvestorPlace
1 year ago
Why Is Aptorum (APM) Stock Up 346% Today?
Aptorum (NASDAQ: APM ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced a merger agreement with YOOV Group. This will be a reverse merger that will see YOOV shareholders hold 90% of the combined company after the deal is complete.
Neutral
Business Wire
1 year ago
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”). The Merger Agreement was approved by Aptorum's and YOOV's boards of directors (each board of directors, the “Board”), respectively. If the Merger Agreement is approved by Ap.
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
Neutral
Business Wire
1 year ago
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. “During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our A.
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
Charts implemented using Lightweight Charts™